Primary fibrositis and its treatment with the pyrazolone derivatives, butazolidin and tandearil.
D000328:Adult; D000367:Age Factors; D003937:Diagnosis, Differential; D003875:Drug Eruptions; D004487:Edema / Q000139:chemically induced; D005260:Female; D005356:Fibromyalgia / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009497:Neurotic Disorders / Q000175:diagnosis; D010113:Oxyphenbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000175:diagnosis; D012737:Sex Factors; D013997:Time Factors
D010653:Phenylbutazone; D010113:Oxyphenbutazone